Adage Capital Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Adage Capital Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,766,070	Closed	-$180M	–	965
2023 Q2	$180M	Buy	1,766,070 +1,296,452	+276%	+$123M	0.39%	53
2023 Q1	$42.7M	Sell	469,618 -836,235	-64%	-$49.1M	0.1%	251
2022 Q4	$49.6M	Buy	1,305,853 +1,065,829	+444%	+$36.7M	0.12%	209
2022 Q3	$6.03M	Sell	240,024 -784,976	-77%	-$21.8M	0.02%	750
2022 Q2	$31.1M	Buy	+1,025,000	New	+$30.6M	0.07%	290
2021 Q4	–	Sell	-17,000	Closed	-$1.71M	–	1123
2021 Q3	$1.71M	Buy	+17,000	New	+$1.99M	﹤0.01%	900
2020 Q2	–	Sell	-80,000	Closed	-$11.5M	–	810
2020 Q1	$11.5M	Sell	80,000 -33,000	-29%	-$6.37M	0.03%	437
2019 Q4	$23.1M	Buy	113,000 +18,000	+19%	+$3.28M	0.06%	362
2019 Q3	$7.63M	Buy	95,000 +50,000	+111%	+$4.24M	0.02%	571
2019 Q2	$4.25M	Buy	+45,000	New	+$3.89M	0.01%	631

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Adage Capital Partners's RETA Position: Q3 2023 in Review

Adage Capital Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,766,070 shares — an estimated $180M sold.

Adage Capital Partners first reported a position in RETA in Q2 2019 and held it in 10 quarters. The position peaked at $180M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Adage Capital Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Adage Capital Partners sold 1,766,070 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $180M.
Adage Capital Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 10 quarters.
Adage Capital Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $180M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Adage Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.